Compare Davita Inc (DVA) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Veritone Inc — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Veritone Inc trades at $1.49 (market cap $121.77M). The key difference: Davita Inc is far larger — about 96.2× Veritone Inc's market cap, and Davita Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| DVA | VERI | |
|---|---|---|
Market Cap | $11.72B | $121.77M |
Sector | Health | Technology |
52-Week High | $240.96 | $8.39 |
52-Week Low | $103.87 | $1.00 |
Enterprise Value | $24.44B | $153.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Veritone (VERI) trades at $1.31, up 4.8% today, with a bullish technical signal despite negative profitability metrics. The company reported Q1 2026 revenue of $90M but missed earnings expectations with a net loss of $111M. Recent business developments include AI partnership expansions with government agencies and new redaction capabilities, while facing multiple securities class action lawsuits alleging improper revenue accounting.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus shows divided sentiment with 46% buy ratings. Key risks include ongoing litigation, execution challenges in achieving profitability, and competitive pressures in the enterprise AI sector. The stock's low price presents speculative potential but requires careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
